Abstract
Eleven postmenopausal women with Parkinson disease and levodopa-induced peak-dose dyskinesias underwent a double-blind, placebo-controlled, crossover study. The active treatment consisted of estrogen replacement therapy for 12 weeks, followed by medroxyprogesterone acetate for 2 weeks. Estrogen replacement therapy-medroxyprogesterone acetate administration significantly improved peak-dose dyskinesia without worsening motor disability, thus suggesting a possible benefit on dyskinesias in postmenopausal women with Parkinson disease.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Akathisia, Drug-Induced / drug therapy*
-
Akathisia, Drug-Induced / etiology
-
Antineoplastic Agents, Hormonal / administration & dosage*
-
Antiparkinson Agents / adverse effects*
-
Cross-Over Studies
-
Double-Blind Method
-
Estrogens / administration & dosage*
-
Female
-
Humans
-
Levodopa / adverse effects
-
Medroxyprogesterone Acetate / administration & dosage*
-
Middle Aged
-
Parkinson Disease / drug therapy
-
Postmenopause
-
Severity of Illness Index
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Antiparkinson Agents
-
Estrogens
-
Levodopa
-
Medroxyprogesterone Acetate